Hope for the Best but Prepare for the Worst: Considerations for Gene Therapy Treatment in Populations with Pre-existing Anti-AAV Antibodies

Time: 3:45 pm
day: Day 1 PM

Details:

• Anti AAV antibody assays or CDx; Context of use: pre-existing versus treatment induced anti-AAV antibodies
• Benefit risk assessment based on medical need and route of administration
• Benefit risk assessment based on pre-existing antibodies
• Patient exclusion or plan to overcome pre-existing immunity

Speakers:

Edit Tarcsa Research Fellow QTAS Site Head, AbbVie Bioresearch Center, Worcester, MA Responsible for developing bioanalytical strategy for biologics and novel therapeutic modalities including gene and cell Read more